| HOME >> MEDICINE >> TECHNOLOGY |
Breast
-- Nicholas Robert, M.D., Fairfax-Northern Virginia Hematology-Oncology,
co-chair US Oncology Breast Cancer Research Committee: Results of a
Phase II study of pemetrexed as first-line chemotherapy for advanced
or metastatic breast cancer
-- Michael Danso, M.D., Virginia Oncology Associates: Phase II trial of
weekly administration of nabpaclitaxel in combination with bevacizumab
in women with metastatic breast cancer (MBC)
-- Mary Ann Allison, M.D., Comprehensive Cancer Centers of Nevada-Siena
and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons
Cancer Center: Phase II study of eribulin mesylate in patients with
locally advanced or metastatic breast cancer (MBC) previously treated
with an anthracycline, taxane, and capecitabine
-- Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III
study of the efficacy of nab-paclitaxel in patients with poor
prognostic factors or with anthracycline-resistant metastatic breast
cancer (MBC)
-- Frankie Holmes, M.D., Texas Oncology-Houston Memorial City,
US Oncology network associate chair Breast Cancer Research Committee,:
Phase II study on transcriptional profiles of triple receptor-negative
breast cancer: Are Caucasian, Hispanic and African-American different?
Lung
-- Charles Weissman, M.D., New York Oncology-Hematology--Latham: Phase
III open-label comparison of gemcitabine/oxaliplatin versus
paclitaxel/carboplatin as first-line therapy for advanced non-small
cell lung cancer (NSCLC)
Genitourinary
-- Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase
II study o
'/>"/>
| SOURCE US Oncology, Inc. Copyright©2008 PR Newswire. All rights reserved |